⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LPCN News
Lipocine Inc.
2026 Asset Growth: Why Federal Compliance Is the New Metric
globenewswire.com
CGC
DFTX
LPCN
KDP
Buprenorphine Patches Market Forecast Intelligence Report 2026-2032: Global, Regional and Country-Level Coverage
globenewswire.com
AMRX
VRTS
TEVA
LPCN
SUN
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
prnewswire.com
LPCN
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
businesswire.com
ABT
AL
GEHC
MED
LH
PHG
LPCN
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
prnewswire.com
LPCN
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
prnewswire.com
LPCN
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
prnewswire.com
LPCN
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
prnewswire.com
LPCN
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
prnewswire.com
LPCN
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
prnewswire.com
LPCN